Product details
Ipamorelin is a synthetic 5-amino-acid pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) engineered as a highly selective GHSR (ghrelin / growth-hormone secretagogue receptor) agonist. Unlike the broader GHRP family (GHRP-2, GHRP-6, Hexarelin), Ipamorelin's selectivity for GHSR over the related receptors that regulate cortisol, prolactin, and ACTH release makes it the most clean GH-selective GHSR agonist in routine research use, the absence of cortisol-axis activation is the defining pharmacological feature relative to the older GHRP analogues.
Peptuno supplies Ipamorelin acetate as a lyophilized powder at ≥99.0% HPLC purity. The short sequence makes synthesis straightforward, and the analytical packet emphasizes peak-integration HPLC plus mass spec, sequence verification by LC-MS/MS is available on request but is rarely the critical test for a 5-residue peptide. Ipamorelin is most commonly combined with a GHRH-pathway agonist (CJC-1295 no-DAC, Sermorelin, or Tesamorelin) in dual-pathway research workflows; the canonical CJC-1295 + Ipamorelin blend is supplied pre-co-lyophilised under the cjc-1295-ipamorelin SKU at standard 5+5 mg ratios with custom ratios via Peptuno's custom-synthesis programme.
FAQ
- What makes Ipamorelin different from GHRP-2 and GHRP-6?
- All three are GHSR (ghrelin receptor) agonists, but they differ in their selectivity profile. GHRP-2 and GHRP-6 also activate the receptors involved in cortisol release, prolactin secretion, and (for GHRP-6 especially) appetite stimulation, these off-target effects can confound research readouts where the GH-axis signal needs to be isolated from broader hypothalamic-pituitary activation. Ipamorelin's pentapeptide design was specifically engineered to retain the GHSR-binding affinity while losing the cortisol-pathway activation, making it the cleanest GHSR-selective agonist in routine use. The trade-off is that GHRP-2 and GHRP-6 produce somewhat larger GH-release magnitudes; Ipamorelin produces a more selective but slightly smaller GH pulse.
- Why is Ipamorelin combined with CJC-1295 rather than used alone?
- Ipamorelin acts on the GHSR; CJC-1295 acts on the GHRH receptor. These are two parallel pathways converging on the same somatotroph cells, and combining a GHSR-pathway agonist with a GHRH-pathway agonist produces GH-release magnitudes substantially larger than either component alone at comparable individual doses. The standard combination ratio is 1:1 by mass (typically 5+5 mg per vial). For research workflows studying GHSR pharmacology in isolation, Ipamorelin alone is the appropriate choice; for GH-release-maximizing workflows, the dual-pathway combination is essentially universal.
- What's the recommended reconstitution and aliquoting approach for Ipamorelin?
- Ipamorelin reconstitutes cleanly in bacteriostatic water for injection at typical research concentrations (1-5 mg/mL is common). The reconstituted solution is reasonably stable at -20 °C as single-use aliquots, but as with the rest of the GH-axis class, freeze-thaw cycling is the dominant source of measured-potency loss. The operational guidance is to split into the smallest workable aliquot volumes immediately after reconstitution and limit thaw cycles to three or fewer. The lyophilized product itself follows the standard 24-month re-test window at -20 °C.
Certificate of Analysis (COA)
The per-lot COA for this product will appear here.